Zoetis' Simparica Trio Shows Superior Heartworm Protection; ZTS Dividend Remains Attractive

gurufocus.com · 2026-10-06

On October 06, 2026, new research published in Parasites & Vectors revealed that Zoetis Inc.'s (NYSE: ZTS) Simparica Trio outperformed competitor NexGard Plus i

TickrTrends take: Zoetis operates in the Healthcare sector where Simparica Trio's demonstrated superiority in heartworm protection represents a competitive strength in its parasiticide portfolio. TickrTrends currently derives an undervalued verdict for ZTS, suggesting the market may not be fully pricing in the value of differentiated product performance in a therapeutic area with consistent consumer demand. Investors focused on valuation should monitor how this product advantage translates into market share gains and revenue growth relative to the company's current trading multiples.

Read the full story at gurufocus.com →